STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances - Tax Rate Impact

Management Commentary

STOK -data report getLinesFromResByArray error: size == 0 getLinesFromResByArray error: size == 0 The Q1 2026 earnings beat was driven primarily by disciplined cost management, with research and development expenses tracking in line with prior guidance. As a clinical-stage biotechnology company, Stoke continues to invest heavily in its lead program, STK-001, an antisense oligonucleotide therapy for Dravet syndrome. During the quarter, the company reported progress in patient enrollment for ongoing Phase 1/2a and Phase 2b studies, though no new efficacy data were released. General and administrative costs remained stable, reflecting a focus on operational efficiency. The net loss of approximately $0.79 per share was narrower than analysts had anticipated, suggesting tighter control over both R&D and G&A spending. Cash and cash equivalents were not disclosed in this earnings data release, but the company has previously highlighted a cash runway extending into mid-2026, which may now extend further given the lower-than-expected burn rate. Stoke’s lack of revenue means that all metrics center on expense management and clinical trial progress. STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0

Forward Guidance

STOK -data report getLinesFromResByArray error: size == 0 getLinesFromResByArray error: size == 0 Management did not provide formal revenue or earnings guidance given the pre-revenue stage, but the company expects to report initial data from the Phase 1/2a dose-escalation cohort later this year. Stoke’s strategic priority remains the timely advancement of STK-001, which aims to restore SCN1A gene function in patients with Dravet syndrome. The company has also been exploring potential expansion into other genetic epilepsies, though no specific timeline has been announced. Risk factors include the inherent uncertainty of clinical development, potential delays in enrollment, and the need for additional capital raises to fund operations beyond the current runway. Investors should note that any future financing activities could dilute existing shareholders. Additionally, regulatory interactions with the FDA and other health authorities may shape the development path and timelines. The company continues to operate with a lean organizational structure, which could limit capacity if multiple programs advance simultaneously. STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0

Market Reaction

STOK -data report getLinesFromResByArray error: size == 0 getLinesFromResByArray error: size == 0 The stock’s modest decline of 1.11% after the earnings beat suggests that the market may be taking a wait-and-see approach, with near-term catalysts centered on clinical data rather than financial results. Analysts have maintained a cautious but constructive view, with several firms reiterating price targets in the range of $5–$8 per share. The EPS beat is a positive signal for cost discipline, but without revenue or major pipeline updates, the stock may lack a near-term catalyst to drive significant upward momentum. What to watch next includes enrollment updates for the Phase 2b portion of STK-001, any safety or efficacy readouts from ongoing studies, and the company’s cash position at the end of Q2. Broader biotech sentiment and interest rate expectations may also influence STOK’s valuation in the coming months. The narrow loss beat, while encouraging, does not fundamentally alter the risk-reward profile of this developmental-stage company. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0STOK Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline Advances getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0